Reagents News and Research

RSS

Genalyte to highlight Maverick Detection System at immunology conferences

Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced that it will launch an Early Access program for its Maverick™ Detection System and multiplexed autoimmune assays at two major immunology meetings in May.

2 May 2012

BD second quarter revenues increase 3.6% to $1.991 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.991 billion for the second fiscal quarter ended March 31, 2012, representing an increase of 3.6 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 2 May 2012

FDA clears Great Basin’s first C. diff molecular diagnostic test

Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.

2 May 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012

New technique could help improve prognosis of patients with brain cancers

Like special-forces troops laser-tagging targets for a bomber pilot, tiny particles that can be imaged three different ways at once have enabled Stanford University School of Medicine scientists to remove brain tumors from mice with unprecedented accuracy.

16 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

Nmnat enzyme plays a critical role in nerve injury

A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection.

31 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

19 Mar 2012

Ventana launches novel platform for special stains

Ventana Medical Systems, Inc., a member of the Roche Group, is now introducing a novel platform for special stains, built on its industry-leading VENTANA BenchMark technology.

19 Mar 2012

DBS introduces novel Multiplex Immunohistochemistry cancer kits

Diagnostic Biosystems, a specialty Immunohistochemistry company, announces its debut as an automated IHC company, introducing the Mosaic 360 System with a product offering of novel Multiplex Immunohistochemistry kits and a complementary line of optimized IHC reagents.

19 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

Thermo Fisher introduces Dionex ICS-5000 system

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Dionex ICS-5000, a capillary high-pressure ion chromatography system that increases separation speeds and provides sharper peaks for high-efficiency ion chromatography.

From Thermo Fisher Scientific Inc. 13 Mar 2012

Thermo Fisher Scientific introduces integrated capillary high-pressure ion chromatography system

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific Dionex ICS-4000, the world's first commercially available integrated capillary high-pressure ion chromatography (HPIC) system, incorporating multiple detector options in one instrument.

From Thermo Fisher Scientific Inc. 12 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0M

GenMark Diagnostics, Inc. today reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2011. The Company will release its full financial statements and related disclosures along with its Form 10-K filing for the period ending December 31, 2011 upon completion of its independent audit, which includes the Company's first Sarbanes-Oxley audit of internal controls, by March 15, 2012.

9 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012